Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775892 | 0.98 | CA12 (0.38) | CA12CA1CA2CA9MGLL | |
| SCHEMBL7435405 | 0.82 | — | — | |
| Heptane SCHEMBL10624295 | 0.77 | TSHR (0.44) | DNM1ALOX15ALDH1A1 | |
| SCHEMBL9012425 | 0.72 | HDAC3 (0.36) | ALOX15ALDH1A1 | |
| SCHEMBL11809610 | 0.71 | CA12 (0.45) | CA12CA1CA2CA9MGLL | |
| SCHEMBL27451502 | 0.71 | ALOX15 (0.38) | CA12CA1CA2CA9DNM1 | |
| SCHEMBL1775890 | 0.70 | CA12 (0.43) | CA12CA1CA2CA9MGLL | |
| SCHEMBL27575203 | 0.69 | DNM1 (0.38) | CA1CA2DNM1ALOX15ALDH1A1 | |
| SCHEMBL28155748 | 0.69 | DNM1 (0.38) | CA1CA2DNM1ALOX15ALDH1A1 | |
| SCHEMBL9011360 | 0.69 | HDAC3 (0.37) | ALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112079-A1 | PHOSPHODIESTERASE INHIBITORS | THE GOV. OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH AND HUMAN SERVICES | 2011-05-12 | — | — | US | disclosed |
| EP-2231669-A1 | PHOSPHODIESTERASE INHIBITORS | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009089027-A1 | PHOSPHODIESTERASE INHIBITORS | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICE, NATIONAL INSTITUTES OF HEALTH (US) | 2009-07-16 | — | — | WO | disclosed |
| US-5162349-A | Mercaptobis/1,3,4-oxa- and -thiadiazoles/ | CIBA-GEIGY CORPORATION (US) | 1992-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112079-A1 | PHOSPHODIESTERASE INHIBITORS | PDE5A, PDE3B, PDE3A | CA12 3542/4885CA1 2560/4885CA2 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.